Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients

Cancer

Volumn 117, Issue 3, 2011, Pages 517-525

  Oh, William K ^a   Vargas, Roberto ^b   Jacobus, Susanna ^a   Leitzel, Kim ^b   Regan, Meredith M ^a   Hamer, Peter ^c   Pierce, Karen ^c   Brown Shimer, Sheryl ^c   Carney, Walter ^c   Ali, Suhail M ^b,d   Kantoff, Philip W ^a   Lipton, Allan ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c Oncogene Science/Siemens Healthcare Diagnostics   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

castration resistant prostate cancer; plasma; prognostic marker; survival; TIMP 1

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; EDETIC ACID; ESTROGEN; GONADORELIN; KETOCONAZOLE; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CASTRATION; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; CASTRATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79251500023     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25394     Document Type: Article

References (39)

1. Chambers AF, Matrisian LM,: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997; 89: 1260-1270.
2. Remacle AG, Noel A, Duggan C, et al. Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer. 1998; 77: 926-931.
3. Rha SY, Yang WI, Kim JH, et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 1998; 5: 875-879.
4. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase and activation of the proenzyme with stromelysin. J Biol Chem. 1992; 267: 4583-4591.
5. Brew K, Dinakarpandian D, Nagase N., Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta. 2000; 1477: 267-283.
6. Bertaux B, Hornebeck W, Eisen AZ, et al. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol. 1991; 97: 679-685.
7. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992; 298: 29-32.
8. Alexander CM, Howard EW, Bissell MJ, Werb Z., Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol. 1996; 135: 1669-1677.
9. Li G, Fridman R, Kim HR., Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999; 59: 6267-6275.
10. Guedez L, Stetler -Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998; 102: 2002-2010.
11. Gasson JC, Golde DW, Kaufman SE, et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature. 1985; 315: 768-771.
12. Yoshiji J, Harris SR, Raso E, et al. Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer. 1998; 75: 81-87.
13. Laleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR., Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). J Cell Sci. 2002; 115: 3427-3428.
14. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005; 104: 2282-2287.
15. Zeng ZS, Cohen AM, Zhang ZF, et al. Elevated tissue inhibitor of metalloproteinase I RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res. 1995; 1: 899-906.
16. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997; 76: 531-536.
17. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. Cancer. 2005; 103: 1676-1684.
18. Ree AH, Florenes VA, Berg JP, et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997; 3: 1623-1628.
19. Guedez L, McMarlin AJ, Kingma DW, et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. Am J Pathol. 2001; 158: 1207-1215.
20. Schroll A-S, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004; 10: 2289-2298.
21. Lipton A, Leitzel K, Chaudri-Ross HA, et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008; 26: 2653-2658.
22. Lipton A, Ali SM, Leitzel K, et al. Elevated plasma TIMP-1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 2007; 109: 1933-1939.
23. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000; 6: 4292-4299.
24. Holten-Anderson MN, Nikolaj M, Nielsen HJ, et al. Tissue inhibitor of metalloproteinases-1 in the post-operative monitoring of colorectal cancer. Eur J Cancer. 2006; 42: 1889-1896.
25. Sorensen MN, Bystrom P, Christensen IJ, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res. 2007; 13: 4117-4122.
26. Lichtinghagen R, Musholt PB, Lein M, et al. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol. 2002; 42: 398-406.
27. Brehmer B, Biesterfeld S, Jakse G., Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003; 6: 217-222.
28. Wang M, Hu Y, Shima I, Stearns ME., IL-10/IL-10 receptor signaling regulates TIMP-1 expression in primary human prostate tumor lines. Cancer Biol Ther. 2002; 1: 556-563.
29. Stearns ME, Rhim J, Wang M., Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999; 5: 189-196.
30. Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ., Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2003; 6: 15-26.
31. Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA., Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer. 1997; 74: 220-223.
32. Vargas R, Jacobus S, Leitzel K, et al. Elevated plasma TIMP-1 levels predict reduced survival in metastatic castration-resistant prostate cancer patients [abstract]. Proc Am Assoc Cancer Res. 2008; 49: 233.
33. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006; 5: 61-66.
34. Halabi S, Small E, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory prostate cancer. J Clin Oncol. 2003; 21: 1232-1237.
35. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007; 57: 43-66.
36. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467.
37. Leitzel K, Kantoff P, Oh WK, et al. Elevated TIMP-1 levels in prostate cancer cell line conditioned medium and hormone-refractory prostate cancer patient plasma [abstract]. In: Proceedings of the ASCO/ASTRO/SUO Prostate Cancer Symposium: A Multidisciplinary Approach, Orlando, FL, February 22-24, 2007. Alexandria, VA: American Society of Clinical Oncology. 2007:119. Abstract 96.
38. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST., TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G-protein and c-src. Biochem Biophys Res Commun. 2003; 312: 1196-1201.
39. Chirco R, Liu X-W, Jung K-K, Kim H-RC., Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006; 25: 99-113.